Skip to main content
SpringerLink
Log in

Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

(S,S)-[18F]FMeNER-D2 is a recently developed positron-emission tomography (PET) radioligand for in vivo quantification of the norepinephrine transporter system. The aim of this study was to provide dosimetry estimates for (S,S)-[18F]FMeNER-D2 based on human whole-body PET measurements.

Methods

PET scans were performed for a total of 6.4 h after the injection of 168.9 ± 31.5 MBq of (S,S)-[18F]FMeNER-D2 in four healthy male subjects. Volumes of interest were drawn on the coronal images. Estimates of the absorbed dose of radiation were calculated using the OLINDA software.

Results

Uptake was largest in lungs, followed by liver, bladder, brain and other organs. Peak values of the percent injected dose (%ID) at a time after radioligand injection were calculated for the lung (21.6%ID at 0.3 h), liver (5.1%ID at 0.3 h), bladder (12.2%ID at 6 h) and brain (2.3%ID at 0.3 h). The largest absorbed dose was found in the urinary bladder wall (0.039 mGy/MBq). The calculated effective dose was 0.017 mSv/MBq.

Conclusion

Based on the distribution and dose estimates, the estimated radiation burden of (S,S)-[18F]FMeNER-D2 is lower than that of [18F]FDG. The radioligand would allow multiple PET examinations in the same research subject per year.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Blakely RD, De Felice LJ, Hartzell HC. Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol 1994;196:263–81.

    PubMed  CAS  Google Scholar 

  2. Galli A, DeFelice LJ, Duke BJ, Moore KR, Blakely RD. Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. J Exp Biol 1995;198:2197–212.

    PubMed  CAS  Google Scholar 

  3. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a norepinephrine disorder. Biol Psychiatry 1999;46:1234–42.

    Article  PubMed  CAS  Google Scholar 

  4. Roy A, Pickar D, De Jong J, Karoum F, Linnoila M. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry 1988;45:849–57.

    PubMed  CAS  Google Scholar 

  5. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;7(Suppl 1):S37–47.

    Article  PubMed  CAS  Google Scholar 

  6. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998;59(Suppl 14):8–10.

    PubMed  CAS  Google Scholar 

  7. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155:693–5.

    PubMed  CAS  Google Scholar 

  8. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:E83.

    Article  PubMed  CAS  Google Scholar 

  9. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699–711.

    Article  PubMed  CAS  Google Scholar 

  10. Schou M, Halldin C, Sovago J, Pike VW, Gulyas B, Mozley PD, et al. Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER. Nucl Med Biol 2003;30:707–14.

    Article  PubMed  CAS  Google Scholar 

  11. Schou M, Halldin C, Sovago J, Pike VW, Hall H, Gulyas B, et al. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 2004;53:57–67.

    Article  PubMed  CAS  Google Scholar 

  12. Seneca N, Gulyas B, Varrone A, Schou M, Airaksinen A, Tauscher J, et al. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.Psychopharmacology (Berl) 2006;188:119–27.

    Article  CAS  Google Scholar 

  13. Seneca N, Andree B, Sjoholm N, Schou M, Pauli S, Mozley PD, et al. Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primates. Nucl Med Commun 2005;26:695–700.

    Article  PubMed  CAS  Google Scholar 

  14. Wrobel MC, Carey JE, Sherman PS, Kilbourn MR. Simplifying the dosimetry of carbon-11-labeled radiopharmaceuticals. J Nucl Med 1997;38:654–60.

    PubMed  CAS  Google Scholar 

  15. Cristy M, Eckerman KF. Specific absorbed fractions of energy at various ages from internal photon sources. I. Methods. ORNL/TM-8381/V1 (Oak Ridge National Laboratory), April 1987.

  16. Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to the fetus from radionuclides in the bladder. Health Phys 1973;25:147–61.

    Article  PubMed  CAS  Google Scholar 

  17. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85:294–310.

    Article  PubMed  CAS  Google Scholar 

  18. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023–7.

    PubMed  Google Scholar 

  19. Fowler JS, Ding YS, Logan J, MacGregor RR, Shea C, Garza V, et al. Species differences in [11C]clorgyline binding in brain. Nucl Med Biol 2001;28:779–85.

    Article  PubMed  CAS  Google Scholar 

  20. Lu JQ, Ichise M, Liow JS, Ghose S, Vines D, Innis RB. Biodistribution and radiation dosimetry of the serotonin transporter ligand 11C-DASB determined from human whole-body PET. J Nucl Med 2004;45:1555–9.

    PubMed  CAS  Google Scholar 

  21. Tipre DN, Lu JQ, Fujita M, Ichise M, Vines D, Innis RB. Radiation dosimetry estimates for the PET serotonin transporter probe 11C-DASB determined from whole-body imaging in non-human primates. Nucl Med Commun 2004;25:81–6.

    Article  PubMed  CAS  Google Scholar 

  22. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538–46.

    PubMed  CAS  Google Scholar 

  23. Takano A, Suhara T, Sudo Y, Inoue M, Hashimoto K, et al. Comparative evaluation of two serotonin transporter ligands in the human brain: [11C](+)McN5652 and [11C]cyanoimipramine. Eur J Nucl Med Mol Imaging 2002;29:1289–97.

    Article  PubMed  CAS  Google Scholar 

  24. Suhara T, Sudo Y, Yoshida K, Okubo Y, Fukuda H, Obata T, et al. Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet 1998;351:332–5.

    Article  PubMed  CAS  Google Scholar 

  25. Ding YS, Lin KS, Garza V, Carter P, Alexoff D, Logan J, et al. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse 2003;50:345–52.

    Article  PubMed  CAS  Google Scholar 

  26. Mejia AA, Nakamura T, Masatoshi I, Hatazawa J, Masaki M, Watanuki S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med 1991;32:699–706.

    PubMed  CAS  Google Scholar 

  27. International Commission on Radiological Protection. ICRP Publication 80. Radiation dose to patients from radiopharmaceutical. Ann ICRP 1998;p 28.

  28. Robeson W, Dhawan V, Belakhlef A, Ma Y, Pillai V, Chaly T, et al. Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects. J Nucl Med 2003;44:961–6.

    PubMed  CAS  Google Scholar 

  29. Deterding TA, Votaw JR, Wang CK, Eshima D, Eshima L, Keil R, et al. Biodistribution and radiation dosimetry of the dopamine transporter ligand. J Nucl Med 2001;42:376–81.

    PubMed  CAS  Google Scholar 

  30. Takano A, Gulyas B, Varrone A, Karlsson P, Schou M, Airaksinen A, Vandenhende F, Tauscher J, Halldin C. Imaging the norepinephrine transporter with positron emission tomography: initial human studies with (S,S)-[18F]FMeNER-D2. Eur J Nucl Med Mol Imaging 2007;48:247.

    Google Scholar 

  31. Guidance on medical exposures in medical and biomedical research. Radiation Protection 99. European Commission 1998.

  32. Beekhuis H. Population radiation absorbed dose from nuclear medicine procedures in The Netherlands. Health Phys 1988;54:287–91.

    PubMed  CAS  Google Scholar 

  33. International Commission on Radiological Protection. ICRP Publication 73.Radiological Protection and Safety in Medicine. Ann ICRP 1996;p 26.

Download references

Acknowledgements

The authors would like to thank Lilly Research Laboratories for providing the precursors and standards. We are grateful to all members of the PET group at the Karolinska Institutet. We also thank Pierre Lafolie for subject recruitment.

Author information

Authors and Affiliations

  1. Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Stockholm, 171 76, Sweden

    Akihiro Takano, Christer Halldin, Andrea Varrone, Per Karlsson, Nils Sjöholm, Magnus Schou, Anu J. Airaksinen & Balázs Gulyás

  2. Radiation Dosimetry Systems, Inc, Palo Alto, CA, USA

    James B. Stubbs

  3. Lilly Research Laboratories, Indianapolis, IN, USA

    Johannes Tauscher

Authors
  1. Akihiro Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christer Halldin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Varrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Per Karlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nils Sjöholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. James B. Stubbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Magnus Schou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anu J. Airaksinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Johannes Tauscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Balázs Gulyás
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Balázs Gulyás.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takano, A., Halldin, C., Varrone, A. et al. Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study. Eur J Nucl Med Mol Imaging 35, 630–636 (2008). https://doi.org/10.1007/s00259-007-0622-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0622-z

Keywords

Search

Navigation